The Menlo team is thrilled to announce we have added a new partner, Greg Yap, to lead investments in the health, medical and life science technology space.
Greg joins us with more than 20 years of experience building and investing in cutting-edge healthcare businesses and technologies. Most recently, he was Entrepreneur in Residence at Illumina Ventures, where he focused on new genomics investments, and was co-founder and CEO of PyrAmes, a stealth mode digital health company. Previously, he was CEO and co-founder of Biodesy, a protein analysis company. He has also held senior roles at Roche/Ventana, where he led their $500 million cancer assay business, and Affymetrix, where he led their genetics and molecular diagnostics businesses.
Biotech is entering a new era, and Greg will bring domain expertise to Menlo at a time when many of the most important discoveries will be made at the intersection of biology and computer science. Advances in machine learning, AI, and big data analysis are enabling new business models and markets and have the potential to impact human health in ways we can scarcely imagine.
We’re planning to invest 15% of Menlo XIV, a $450 million fund, in early stage companies aiming at breakthrough improvements in health. This new strategy builds on several recent investments in the sector, including Synthego, Cofactor Genomics, Clear Labs, and Recursion Pharmaceuticals. Although recently we have focused our investment on consumer and enterprise technologies, we have a long history in biotech, including the incubation of Gilead Sciences.
We’re thrilled to welcome Greg to help us make investments in companies and technologies that will change lives for the better.